Man Group PLC Ultragenyx Pharmaceutical Inc. Transaction History

Man Group PLC

$36 Billion
Q3 2024

A detailed history of Man Group PLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Man Group PLC holds 327,203 shares of RARE stock, worth $14.1 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

327,203

Previous 628,726 47.96%

Holding current value

$14.1 Million

Previous $25.8 Million 29.66%

% of portfolio

0.05%

Previous 0.07%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$40.21 - $59.36 $12.1 Million - $17.9 Million	-301,523 Reduced 47.96%	327,203 $18.2 Million
Q2 2024 Aug 14, 2024	BUY	$37.42 - $51.61 $17.8 Million - $24.5 Million	475,085 Added 309.22%	628,726 $25.8 Million
Q1 2024 May 15, 2024	BUY	$43.02 - $53.69 $2.83 Million - $3.53 Million	65,830 Added 74.97%	153,641 $7.17 Million
Q4 2023 Feb 14, 2024	BUY	$31.73 - $49.19 $2.05 Million - $3.17 Million	64,473 Added 276.26%	87,811 $4.2 Million
Q3 2023 Nov 14, 2023	SELL	$34.92 - $46.66 $661,349 - $883,693	-18,939 Reduced 44.8%	23,338 $831,000
Q2 2023 Aug 14, 2023	BUY	$37.35 - $52.15 $827,526 - $1.16 Million	22,156 Added 110.11%	42,277 $1.95 Million
Q1 2023 May 15, 2023	SELL	$36.99 - $48.71 $669,149 - $881,163	-18,090 Reduced 47.34%	20,121 $806,000
Q4 2022 Feb 14, 2023	BUY	$33.72 - $46.33 $127,225 - $174,803	3,773 Added 10.96%	38,211 $1.77 Million
Q3 2022 Nov 14, 2022	BUY	$39.96 - $66.14 $330,149 - $546,448	8,262 Added 31.56%	34,438 $1.43 Million
Q2 2022 Aug 15, 2022	BUY	$45.8 - $85.4 $890,901 - $1.66 Million	19,452 Added 289.29%	26,176 $1.56 Million
Q1 2022 May 16, 2022	BUY	$62.2 - $84.4 $418,232 - $567,505	6,724 New	6,724 $488,000
Q2 2021 Aug 16, 2021	SELL	$92.19 - $115.71 $1.53 Million - $1.93 Million	-16,645 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$106.9 - $167.73 $3.05 Million - $4.78 Million	-28,503 Reduced 63.13%	16,645 $1.9 Million
Q4 2020 Feb 16, 2021	BUY	$84.4 - $177.39 $1.06 Million - $2.23 Million	12,555 Added 38.52%	45,148 $6.25 Million
Q3 2020 Nov 16, 2020	BUY	$72.98 - $90.0 $293,087 - $361,440	4,016 Added 14.05%	32,593 $2.68 Million
Q2 2020 Aug 14, 2020	SELL	$46.91 - $78.22 $411,447 - $686,067	-8,771 Reduced 23.48%	28,577 $2.24 Million
Q1 2020 May 15, 2020	SELL	$33.8 - $62.9 $1.99 Million - $3.7 Million	-58,795 Reduced 61.15%	37,348 $1.66 Million
Q4 2019 Feb 18, 2020	BUY	$36.08 - $45.83 $1.62 Million - $2.05 Million	44,797 Added 87.25%	96,143 $4.11 Million
Q3 2019 Nov 14, 2019	SELL	$42.5 - $63.11 $689,222 - $1.02 Million	-16,217 Reduced 24.0%	51,346 $2.2 Million
Q2 2019 Aug 14, 2019	SELL	$54.93 - $74.36 $557,100 - $754,159	-10,142 Reduced 13.05%	67,563 $4.29 Million
Q1 2019 May 15, 2019	BUY	$39.87 - $69.36 $1.38 Million - $2.4 Million	34,662 Added 80.53%	77,705 $5.39 Million
Q4 2018 Feb 14, 2019	SELL	$38.89 - $77.3 $246,601 - $490,159	-6,341 Reduced 12.84%	43,043 $1.87 Million
Q3 2018 Nov 14, 2018	BUY	$71.81 - $90.15 $3.55 Million - $4.45 Million	49,384 New	49,384 $3.77 Million

Others Institutions Holding RARE

# of Institutions

325

Shares Held

85.5M

Call Options Held

520K

Put Options Held

406K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.01B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account